Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

144 results about "Claudin" patented technology

Claudins are a family of proteins which, along with occludin, are the most important components of the tight junctions (zonulae occludentes). Tight junctions establish the paracellular barrier that controls the flow of molecules in the intercellular space between the cells of an epithelium. They have four transmembrane domains, with the N-terminus and the C-terminus in the cytoplasm.

Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.
Owner:CHUGAI PHARMA CO LTD

Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium

InactiveUS20060078941A1Highligthing the divergence of gene expressionMicrobiological testing/measurementBiological testingKallikrein-10Gene family
Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1 / Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2 / differentially expressed in ovarian carcinoma 2 (Dab2 / DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1 / Ep-CAM by monoclonal chimeric / humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas. Claudin-3 and claudin-4 being receptors for Clostridium Perfringens enterotoxin, this toxin may be used as a novel therapeutic agent to treat ovarian serous papillary tumors.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS

Noveltreatment for neurological disorders

Provided are novel drugs and methods in the treatment as well as diagnosis of neurological disorders such as Alzheimer's disease and amyloid-beta pathology / amyloidosis. More specifically, the use of erythropoietin and analogs thereof for the treatment of Aβ peptide related brain impairments is described. Furthermore, the use of claudin-5 and variants thereof as biomarker for Alzheimer's disease and for the progression of Alzheimer's disease, respectively, is provided.
Owner:UNIV ZURICH

Cancer-specific promoters

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-specific and ovarian cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of fatty acid synthase and claudin 4 promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. Two ovarian cancer-specific sequences utilize specific regions of hTERT and survivin promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

InactiveUS20150132253A1Effectively preventingEffectively treatingHeavy metal active ingredientsOrganic active ingredientsDiseaseCombined Modality Therapy
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:ASTELLAS PHARMA INC +1

Hcv coreceptor and methods of use thereof

The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.
Owner:THE ROCKEFELLER UNIV

Method for Opening Tight Junctions

The present invention is directed to a method and use of RNA interference (RNAi) for the transient, reversible and controlled opening of the tight junctions of the blood brain barrier and / or the blood retinal barrier. This method may be used in the treatment of many diseases and disorders which require the opening of the blood brain barrier and / or blood retinal barrier. Such methods generally involve the use of an RNAi-inducing agent, such as siRNA, miRNA, shRNA or an RNAi-inducing vector whose presence within a cell results in production of an siRNA or shRNA, targeting tight junction proteins to open the blood brain barrier and / or blood retinal barrier.
Owner:TRINITY COLLEGE DUBLIN

Method for detecting injury to the brain

Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
Owner:TEMPLE UNIVERSITY

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS +1

Claudin 18.2-targeting CAR molecule, immune cell modified by Claudin 18.2-targeting CAR molecule and application of Claudin 18.2-targeting CAR molecule

The present invention discloses a nucleic acid construct. The nucleic acid construct is characterized in that the nucleic acid construct has a structure as shown in the formula car-[(IRES)-f]<m>, wherein the IRES is a sequence of an internal ribosome entry site, f encodes a functional protein F, m is 0 or a non-0 natural number, car encodes a CAR, the CAR comprises (a) an extracellular binding domain that specifically recognizes CLDN18.2, (b) a hinge domain, (c) a transmembrane domain, (d) a costimulating intracellular domain, and (e) a signal transduction domain, the extracellular binding domain comprises scFv, and the amino acid sequences and functions of the extracellular binding structural domain are described in the specification. The CAR molecule provided by the invention has excellent safety and effectiveness and shows a very good tumor inhibition effect.
Owner:L&L BIOPHARMA CO LTD

Peptide mimotopes of claudin 18.2 and uses thereof

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
Owner:JPT PEPTIDE TECH +1

Antibodies binding human Claudin 18.2 and uses thereof

An isolated monoclonal antibody that specifically binds human Claudin 18.2. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a diagnostic or treatment method using an anti-Claudin 18.2 antibody of the invention.
Owner:BEIJING MABWORKS BIOTECH

Application of lactobacillus reuteri in preventing and relieving ulcerative colitis

The invention discloses application of lactobacillus reuteri in preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. Lactobacillus reuteri CCFM1135 can tolerate the gastrointestinal environment of a human body, significantly reduce the disease activity index during the ulcerative colitis, improve colon mucosal injury, reduce MPO activity, reduce the content of proinflammatory factors TNF-alpha, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate the transcription levels of colon antibacterial peptides Reg3g and Reg3b, improve the diversity of intestinal flora, and reduced the relative abundance of acinetobacter in excrement.
Owner:JIANGNAN UNIV

Lactobacillus plantarum for relieving ulcerative colitis and application thereof

The invention discloses a lactobacillus plantarum for relieving ulcerative colitis and application thereof, and belongs to the technical field of functional microorganisms. The lactobacillus plantarum CCFM1117 can tolerate the gastrointestinal environment of a human body, reduce weight loss in the ulcerative colitis disease period, improve fecal characters and hemafecia conditions, relieve length shortening of the colon, improve colonic mucosal injury, reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in the colon, up-regulate the gene transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, increase the content of short-chain fatty acid, increase the abundance of short-chain fatty acid producing bacteria Coprococcus and butyric acid producing bacteria Faecalibacterium, and improve the diversity of intestinal flora.
Owner:JIANGNAN UNIV

Bifidobacterium longum subsp.infantis for relieving colitis and application thereof

PendingCN114574390ANo side effectsLower disease activity indexBacteriaDigestive systemBiotechnologyMyeloperoxidase level
The invention discloses bifidobacterium longum subsp.infantis for relieving colitis and application, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1210 provided by the invention has the immunoregulation capability, and can improve the intestinal barrier and relieve colitis. Animal experiments prove that through intervention of the bifidobacterium longum subsp.infantis CCFM1210, tissue damage of a mouse can be remarkably relieved, the myeloperoxidase level can be remarkably reduced, the content of tight junction protein in colon tissue can be remarkably increased, the levels of proinflammatory cytokines IL-1beta and IL-6 can be remarkably reduced, and the level of an anti-inflammatory cytokine IL-10 can be remarkably increased; the concentration of butyric acid is obviously increased, the diversity of intestinal flora is obviously improved, and the disorder of the flora is relieved. Compared with a traditional medicine for treating colitis, a medicine or a probiotic preparation prepared from the bifidobacterium longum subsp. Infantis CCFM1210 disclosed by the invention has certain advantages and has a wide market prospect.
Owner:JIANGNAN UNIV

Application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis

The invention discloses an application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. The lactobacillus rhamnosus can tolerate the gastrointestinal environment of a human body, significantly reduce weight loss during the period of ulcerative colitis, improve fecal traits and hematochezia, improve colon mucosal injury, reduce MPO activity, and reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in colon. The transcription levels of colon close junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, antibacterial peptides Reg3g and Reg3b and mucoprotein MUC2 are up-regulated, the abundance of short-chain fatty acid producing bacteria Coprococcus and Faecalibacterium and the content of short-chain fatty acid are improved, the abundance of beneficial bacteria Lactobacillus in intestinal tracts is increased, the abundance of the conditional pathogenic bacteria Acinetobacter is reduced, and the abundance and diversity of intestinal flora are increased.
Owner:JIANGNAN UNIV

Antibody combined with tight junction protein-18.2 and application of antibody

The present disclosure relates to an antibody or an antigen-binding portion thereof combined with a tight junction protein-18. 2 and application of the antibody or the antigen-binding portion thereof.The antibody can be combined with the tight junction protein-18. 2 with high affinity, and can be used for detecting the tight junction protein-18. 2, and diagnosing, treating or preventing diseasesrelated to cells of the tight junction protein-18. 2.
Owner:CHENGDU CONMED BIOSCI CO LTD +2

Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection

ActiveUS20110236347A1Neutralize HCV infectivityLess susceptible to developmentAnimal cellsPeptide/protein ingredientsExtracellular StructureHybridoma cell
The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Bifidobacterium capable of relieving colitis and application thereof

The invention discloses a rapid screening method and application of bifidobacterium capable of relieving colitis and belongs to the technical field of biology. The bifidobacterium pseudocatenulatum is preserved in China Center for Type Culture Collection (CCTCC), Wuhan, on July 5, 2021, and the preservation number is CCTCC M2021820. The bifidobacterium pseudocatenulatum can be used for significantly improving weight loss, colon length and disease activity index of mice during DSS-inducing colitis, enhancing intestinal barrier integrity, and inhibiting tissue damage, myeloperoxidase (MPO) activity, PGE2 level and proinflammatory factors. Compared with mice of a model group, the bifidobacterium pseudocatenulatum KLDS N2 has the advantages that the expression of proinflammatory cytokine mRNA of a DSS stimulated mouse is obviously down-regulated, and the expression of mRNA of mucoprotein and tight junction protein is up-regulated.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Claudin-18.2-specific immunoreceptors and t cell epitopes

The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
Owner:BIONTECH CELL & GENE THERAPIES +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products